Gardasil puts Australia on track to eliminate cervical cancer
Résumé détaillé
Gardasil, the vaccine against the human papillomavirus that causes almost all cervical cancers, was developed at The University of Queensland, and is the world’s first vaccine to…
Gardasil, the vaccine against the human papillomavirus that causes almost all cervical cancers, was developed at The University of Queensland (UQ), and is the world’s first vaccine to prevent a cancer.
In the 20 years since the first official doses were given to two Brisbane teenagers in August 2006, more than 600 million doses of Gardasil have been administered worldwide, and Australia is on track to become the first country to eliminate cervical cancer. The target is 2035.
The Australian government’s 2025 Cervical Cancer Elimination Progress Report found no new cases in Australian women under 25 in 2021, a result “almost certainly due to the impact of HPV vaccination alongside the National Cervical Cancer Screening Program”.
The Gardasil story begins with the friendship between now-Emeritus Professor Ian Frazer, an Australian Scottish-born immunologist, who met Dr Jian Zhou in 1989 at the University of Cambridge, where Zhou had a visiting fellowship from China.
Frazer invited Zhou and his wife, fellow researcher Dr Xiao Yi Sun, to join him at UQ, where they worked on ways to prevent infection by strains of human papillomavirus previously shown to cause cervical cancer. The team began manually writing gene sequences – and in 1991, spotted virus-like particles on an electron micrograph. These contained no viral genetic material, so were non-infectious.
“Jian said, ‘We’ve got the shell of the virus!’ and I said, ‘Yes, and we’ve probably got a vaccine’,” said Frazer.
Their work at UQ was funded by National Health and Medical Research Council grants. After licensing and further development, clinical trials began in 1997, but sadly, Zhou died in 1999, before seeing the culmination of their research in the first dose, some seven years later.
Bringing the vaccine to market meant clinical trials involving more than 50,000 participants, manufacturing at scale, and years of regulatory work – and that is where partnerships came in.
Dr Dean Moss, who heads the university’s…
Début de l'article, extrait de Australian Financial Review. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.afr.com)